Oculis (OCS) Competitors $14.76 +0.01 (+0.07%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends OCS vs. LBPH, IDYA, ARWR, AKRO, CGON, AMPH, KROS, WVE, MIRM, and APGEShould you be buying Oculis stock or one of its competitors? The main competitors of Oculis include Longboard Pharmaceuticals (LBPH), IDEAYA Biosciences (IDYA), Arrowhead Pharmaceuticals (ARWR), Akero Therapeutics (AKRO), CG Oncology (CGON), Amphastar Pharmaceuticals (AMPH), Keros Therapeutics (KROS), Wave Life Sciences (WVE), Mirum Pharmaceuticals (MIRM), and Apogee Therapeutics (APGE). These companies are all part of the "pharmaceutical products" industry. Oculis vs. Longboard Pharmaceuticals IDEAYA Biosciences Arrowhead Pharmaceuticals Akero Therapeutics CG Oncology Amphastar Pharmaceuticals Keros Therapeutics Wave Life Sciences Mirum Pharmaceuticals Apogee Therapeutics Oculis (NASDAQ:OCS) and Longboard Pharmaceuticals (NASDAQ:LBPH) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability, dividends and community ranking. Which has more volatility & risk, OCS or LBPH? Oculis has a beta of -0.16, indicating that its share price is 116% less volatile than the S&P 500. Comparatively, Longboard Pharmaceuticals has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Do analysts rate OCS or LBPH? Oculis currently has a consensus target price of $29.20, suggesting a potential upside of 97.83%. Longboard Pharmaceuticals has a consensus target price of $59.56, suggesting a potential downside of 0.41%. Given Oculis' stronger consensus rating and higher probable upside, analysts clearly believe Oculis is more favorable than Longboard Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oculis 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Longboard Pharmaceuticals 0 Sell rating(s) 5 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.44 Is OCS or LBPH more profitable? Longboard Pharmaceuticals has a net margin of 0.00% compared to Oculis' net margin of -8,043.28%. Longboard Pharmaceuticals' return on equity of -33.03% beat Oculis' return on equity.Company Net Margins Return on Equity Return on Assets Oculis-8,043.28% -71.31% -56.85% Longboard Pharmaceuticals N/A -33.03%-30.90% Does the MarketBeat Community favor OCS or LBPH? Longboard Pharmaceuticals received 37 more outperform votes than Oculis when rated by MarketBeat users. However, 89.66% of users gave Oculis an outperform vote while only 75.00% of users gave Longboard Pharmaceuticals an outperform vote. CompanyUnderperformOutperformOculisOutperform Votes2689.66% Underperform Votes310.34%Longboard PharmaceuticalsOutperform Votes6375.00% Underperform Votes2125.00% Which has better earnings & valuation, OCS or LBPH? Longboard Pharmaceuticals has lower revenue, but higher earnings than Oculis. Longboard Pharmaceuticals is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOculis$980K609.98-$98.92M-$1.93-7.65Longboard PharmaceuticalsN/AN/A-$54.42M-$2.23-26.82 Do insiders & institutionals believe in OCS or LBPH? 22.3% of Oculis shares are held by institutional investors. Comparatively, 63.3% of Longboard Pharmaceuticals shares are held by institutional investors. 4.6% of Longboard Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media prefer OCS or LBPH? In the previous week, Longboard Pharmaceuticals had 2 more articles in the media than Oculis. MarketBeat recorded 3 mentions for Longboard Pharmaceuticals and 1 mentions for Oculis. Longboard Pharmaceuticals' average media sentiment score of 1.50 beat Oculis' score of 0.67 indicating that Longboard Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Longboard Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryLongboard Pharmaceuticals beats Oculis on 10 of the 17 factors compared between the two stocks. Ad Paradigm Press[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.Click here now for the urgent details on this hidden play. Get Oculis News Delivered to You Automatically Sign up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCS vs. The Competition Export to ExcelMetricOculisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$597.78M$7.00B$5.38B$8.84BDividend YieldN/A8.11%5.13%4.09%P/E Ratio-7.6511.01105.9717.81Price / Sales609.98388.961,243.81162.56Price / CashN/A52.5940.2936.29Price / Book5.4310.377.086.50Net Income-$98.92M$153.60M$119.58M$226.22M7 Day Performance4.38%4.59%2.25%4.04%1 Month Performance-9.23%-6.28%-2.33%4.94%1 Year Performance49.92%33.39%33.91%29.30% Oculis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCSOculis2.8938 of 5 stars$14.76+0.1%$29.20+97.8%+51.1%$597.78M$980,000.00-7.652LBPHLongboard Pharmaceuticals1.7609 of 5 stars$59.80+0.1%$59.56-0.4%+1,358.5%$2.34BN/A-26.8220Positive NewsIDYAIDEAYA Biosciences4.179 of 5 stars$26.79+0.7%$53.67+100.3%-15.2%$2.32B$3.92M-11.5080High Trading VolumeARWRArrowhead Pharmaceuticals3.6142 of 5 stars$18.54+1.4%$45.33+144.5%-36.0%$2.30B$240.74M-3.97400Upcoming EarningsAnalyst ForecastNews CoverageAKROAkero Therapeutics4.061 of 5 stars$32.73+4.9%$46.83+43.1%+105.3%$2.28BN/A-8.7330Insider TradeCGONCG Oncology3.1834 of 5 stars$33.47+3.5%$63.88+90.8%N/A$2.26B$200,000.000.0061Positive NewsAMPHAmphastar Pharmaceuticals4.8709 of 5 stars$45.46+2.0%$60.33+32.7%-18.9%$2.19B$723.55M14.821,761Analyst ForecastPositive NewsGap UpKROSKeros Therapeutics3.5847 of 5 stars$55.92+3.9%$88.89+59.0%+84.2%$2.18B$651,000.00-10.73100Analyst ForecastWVEWave Life Sciences4.827 of 5 stars$14.27-0.6%$22.22+55.7%+164.3%$2.18B$113.31M-12.93240Analyst ForecastMIRMMirum Pharmaceuticals4.3331 of 5 stars$44.73+2.9%$57.73+29.1%+39.8%$2.15B$186.37M-22.14140APGEApogee Therapeutics2.4626 of 5 stars$43.46+1.4%$78.50+80.6%+152.2%$1.96BN/A-17.9691 Related Companies and Tools Related Companies LBPH Competitors IDYA Competitors ARWR Competitors AKRO Competitors CGON Competitors AMPH Competitors KROS Competitors WVE Competitors MIRM Competitors APGE Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OCS) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oculis Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Oculis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OCS Stock Alerts